AU2014276885B2 - Pharmaceutical preparation - Google Patents

Pharmaceutical preparation Download PDF

Info

Publication number
AU2014276885B2
AU2014276885B2 AU2014276885A AU2014276885A AU2014276885B2 AU 2014276885 B2 AU2014276885 B2 AU 2014276885B2 AU 2014276885 A AU2014276885 A AU 2014276885A AU 2014276885 A AU2014276885 A AU 2014276885A AU 2014276885 B2 AU2014276885 B2 AU 2014276885B2
Authority
AU
Australia
Prior art keywords
solution
alpha
isotope
selective binder
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014276885A
Other languages
English (en)
Other versions
AU2014276885A1 (en
Inventor
Alan Cuthbertson
Janne Olsen FRENVIK
Olav B. Ryan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU2014276885A1 publication Critical patent/AU2014276885A1/en
Application granted granted Critical
Publication of AU2014276885B2 publication Critical patent/AU2014276885B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Saccharide Compounds (AREA)
  • Extraction Or Liquid Replacement (AREA)
AU2014276885A 2013-06-05 2014-06-05 Pharmaceutical preparation Active AU2014276885B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1310028.4 2013-06-05
GBGB1310028.4A GB201310028D0 (en) 2013-06-05 2013-06-05 Pharmaceutical preparation
PCT/EP2014/061743 WO2014195423A1 (en) 2013-06-05 2014-06-05 Pharmaceutical preparation

Publications (2)

Publication Number Publication Date
AU2014276885A1 AU2014276885A1 (en) 2015-12-17
AU2014276885B2 true AU2014276885B2 (en) 2018-12-06

Family

ID=48805787

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014276885A Active AU2014276885B2 (en) 2013-06-05 2014-06-05 Pharmaceutical preparation

Country Status (36)

Country Link
US (2) US20160114063A1 (hr)
EP (1) EP3003401B1 (hr)
JP (1) JP6580559B2 (hr)
KR (1) KR102321763B1 (hr)
CN (1) CN105592863B (hr)
AP (1) AP2015008894A0 (hr)
AU (1) AU2014276885B2 (hr)
BR (1) BR112015030298A2 (hr)
CA (1) CA2914278C (hr)
CL (1) CL2015003554A1 (hr)
CR (1) CR20150642A (hr)
CU (1) CU24535B1 (hr)
DK (1) DK3003401T3 (hr)
DO (1) DOP2015000294A (hr)
EA (1) EA201501174A1 (hr)
ES (1) ES2782624T3 (hr)
GB (1) GB201310028D0 (hr)
HR (1) HRP20200456T1 (hr)
IL (1) IL242704B (hr)
LT (1) LT3003401T (hr)
MA (1) MA38650B1 (hr)
MX (1) MX366028B (hr)
MY (1) MY180717A (hr)
NI (1) NI201500173A (hr)
PE (1) PE20160215A1 (hr)
PH (1) PH12015502715B1 (hr)
PL (1) PL3003401T3 (hr)
PT (1) PT3003401T (hr)
RS (1) RS60091B1 (hr)
SA (1) SA515370233B1 (hr)
SG (1) SG11201509856RA (hr)
SI (1) SI3003401T1 (hr)
TN (1) TN2015000527A1 (hr)
UA (1) UA120352C2 (hr)
WO (1) WO2014195423A1 (hr)
ZA (1) ZA201600027B (hr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201600158D0 (en) * 2016-01-05 2016-02-17 Bayer As Purification method
GB201600161D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope purification method
CA3208778A1 (en) 2021-01-22 2022-07-28 Bayer Aktiengesellschaft Lrrc15 antibodies and conjugates thereof
NO347755B1 (en) * 2021-10-21 2024-03-18 Blue Wave Therapeutics Gmbh Peptide-coupled alginate gels comprising radionuclides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012131378A2 (en) * 2011-03-29 2012-10-04 Algeta Asa Pharmaceutical preparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5749042A (en) * 1997-01-28 1998-05-05 Battelle Memorial Institute Bismuth generator method
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
US8481694B2 (en) * 2009-04-29 2013-07-09 Bio-Rad Laboratories, Inc. Purification of immunoconjugates
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012131378A2 (en) * 2011-03-29 2012-10-04 Algeta Asa Pharmaceutical preparation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PURKL S ET AL, "A rapid method for alpha-spectrometric analysis of radium isotopes in natural waters using ion-selective membrane technology", APPLIED RADIATION AND ISOTOPES, ELSEVIER, OXFORD, GB, (2003-10-01), vol. 59, no. 4,p245 - 254 *
S Purkl ET AL, "Solid-phase extraction using Empore(TM) Radium Rad Disks to separate radium from thorium", Journal of Radioanalytical and Nuclear Chemistry, (2003), p473 - 480, URL: http://rd.springer.com/article/10.1023%2FA%3A1024547631964 *

Also Published As

Publication number Publication date
RS60091B1 (sr) 2020-05-29
MX366028B (es) 2019-06-21
US20220023449A1 (en) 2022-01-27
SG11201509856RA (en) 2015-12-30
JP2016521700A (ja) 2016-07-25
MA38650B1 (fr) 2019-05-31
NI201500173A (es) 2016-01-06
CA2914278C (en) 2022-11-01
PE20160215A1 (es) 2016-05-22
ES2782624T3 (es) 2020-09-15
KR20160030893A (ko) 2016-03-21
PT3003401T (pt) 2020-04-09
ZA201600027B (en) 2018-07-25
PH12015502715A1 (en) 2016-03-28
CN105592863A (zh) 2016-05-18
NZ714737A (en) 2021-02-26
WO2014195423A1 (en) 2014-12-11
KR102321763B1 (ko) 2021-11-05
MX2015016726A (es) 2016-06-28
CR20150642A (es) 2016-07-22
US20160114063A1 (en) 2016-04-28
CU20150174A7 (es) 2016-06-29
DOP2015000294A (es) 2016-03-15
AU2014276885A1 (en) 2015-12-17
CL2015003554A1 (es) 2016-07-15
LT3003401T (lt) 2020-06-25
IL242704B (en) 2020-06-30
EP3003401A1 (en) 2016-04-13
UA120352C2 (uk) 2019-11-25
EA201501174A1 (ru) 2016-10-31
CU24535B1 (es) 2021-07-02
AP2015008894A0 (en) 2015-12-31
TN2015000527A1 (en) 2017-04-06
HRP20200456T1 (hr) 2020-06-26
JP6580559B2 (ja) 2019-09-25
SA515370233B1 (ar) 2019-05-30
DK3003401T3 (da) 2020-04-06
MY180717A (en) 2020-12-07
GB201310028D0 (en) 2013-07-17
CN105592863B (zh) 2020-03-10
EP3003401B1 (en) 2020-01-15
SI3003401T1 (sl) 2020-06-30
MA38650A1 (fr) 2018-03-30
PH12015502715B1 (en) 2016-03-28
CA2914278A1 (en) 2014-12-11
PL3003401T3 (pl) 2020-07-27
BR112015030298A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
US20220023449A1 (en) Pharmaceutical preparation
AU2012235881B2 (en) Pharmaceutical preparation
US10729794B2 (en) Isotope purification method
US20210130253A1 (en) Purification method
EA008195B1 (ru) Применение тория-227 в лучевой терапии заболеваний мягких тканей
NZ714737B2 (en) Pharmaceutical preparation
JP6901498B2 (ja) 同位体調製方法
EA040260B1 (ru) Фармацевтический препарат для применения в эндорадионуклидной терапии
US20240091391A1 (en) Mof for radiotherapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)